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Introduction: In an attempt to search for genes with abnormal
expression in cancers, Suppressed in Lung Cancer (SLAN, also
known as KIAA0256) is found underexpressed in human lung cancer
tissues by quantitative real-time PCR (Q-RT-PCR). The study set
out to characterize SLAN protein and explore its cellular functions.
Methods: SLAN or its specific short hairpin RNA, full length or
various deletion mutants were overexpressed in 293T or lung cancer
cell lines, and cell proliferation, cell cycle, mitosis progression, and
spindle configuration were surveyed.
Results: SLAN and its deletion mutants are localized to many
subcellular locations such as endoplasmic reticulum (ER), nucleus,
nucleolus, spindle pole and midbody, suggesting SLAN may func-
tion as a multifunctional protein. Overexpression of SLAN per se or
its short hairpin RNAs (shRNAs) inhibits or accelerates cell prolif-
eration through prolonging or shortening mitosis. Time-lapse micro-
scopic recording reveals that cells overexpressing exogenous SLAN
are arrested in mitosis or cannot undergo cytokinesis. SLAN 2–551
mutants drastically arrest cells in mitosis, where - and -tubulin are
disorganized. SLAN employs C-terminal to interact with Aurora-A,
a key mitosis regulator and an oncogenic kinase associated with a
wide range of human cancers. SLAN negatively regulates the
activity of Aurora-A by directly inhibiting kinase activity in vitro or
reducing the level of active Aurora-A in cells. SLAN is frequently
reduced in lung cancer tissues overexpressing Aurora-A, arguing for
the necessity to suppress SLAN during the Aurora-A-associated
cancer formation.
Conclusions: Taken together, we have identified a novel protein
SLAN downregulated in lung caner, having multiple subcellular
localization including spindle matrix and midbody, inhibiting cell
proliferation and Aurora-A.
Key Words: SLAN, KIAA0256, Mitosis, Tumor suppressor,
Aurora-A.
(J Thorac Oncol. 2011;6: 988–997)
With the accomplishment of human genome project,biomedical research has approached the postgenomic
era. It becomes imperative to prioritize studies of the genes
with fundamental importance in human genome. Cancers are
notorious for their high prevalence and continue to be one of
the leading causes of death in the world. Cancers arise with
largely unknown mechanisms, leading to the difficulties for
their therapeutic treatment. Growing evidence demonstrates
that cancers are caused by accumulated gene mutations,1,2
prompting us to look for genes with altered expression in the
disease.
Lung cancer, classified into two broad categories his-
tologically, i.e., small cell carcinoma and non-small cell
carcinoma, is a major cause of cancer-related mortality
worldwide with more than 1 million new cases diagnosed per
year.3,4 A range of prognostic biomarkers involving genes
that regulate cell cycle progression and apoptosis, and inva-
sion and metastasis have been described in lung cancer. For
example, certain polymorphisms, expression level, and sub-
cellular localization of Aurora-A, a mitosis regulator with
oncogenic activity, are suggested to serve as a prognostic
factor of lung cancers.5–7 The oncogenic Aurora-A is a key
regulator of mitosis and is found overexpressed in a wide
range of human cancers, prioritizing Aurora-A as a target of
anticancer therapy and thereby stimulating the investment on
the development of Aurora-A inhibitor.8–15
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To explore more molecular anticancer targets, we had
adopted microarray analyses to search for the new genes with
potential involvement in lung cancer formation. Several
genes are noted because of their altered expression patterns in
lung cancer. From a list of such genes, suppressed in lung
cancer (SLAN also known as SECISBP2L or KIAA0256) is
specifically selected because of the inhibitory activity of
SLAN on cell proliferation and Aurora-A. SLAN is a novel
gene with limited reports focusing on it so far. SLAN con-
tains a ribosomal L7Ae/Gadd45 signature at its C-terminal
which is analogous to the functional C-terminal fragment of
SBP2, a protein responsible for selenocysteine insertion;
however, the function of SLAN remains to be determined.16
Altered expression of SLAN is detected in schizophrenia,17
age-related cataract,18 and cancers,19,20 hinting SLAN might
be involved in the pathogenesis of some human diseases. Our
analyses in the studies reveal the involvement of SLAN in
cancer formation. SLAN is down-regulated in a number of
lung cancer tissues at messenger RNA (mRNA) and protein
level. SLAN is localized to several subcellular locations and
negatively regulates cell proliferation through the interfer-
ence with mitosis progression. At last, SLAN interacts with
and inhibits Aurora-A, a mitotic oncokinase21–23 and a key
mitosis or meiosis regulator,24–26 providing a connection of
SLAN to molecular oncogenesis and mitosis regulation.
MATERIALS AND METHODS
Tissue Procurement, Total RNA Preparation,
and Reverse Transcription
The study protocol had the approval of the ethics
committee at Taipei Veterans General Hospital.27 No patients
had previously received any neoadjuvant treatment such as
chemotherapy before the surgery. All patients gave informed
consents and signed the consent form individually. The sam-
ples were obtained from a nonnecrotic area of the tumor and
from adjacent nontumorous tissue. Study samples, including
tumor and adjacent normal tissues, were obtained after oper-
ation, and adjacent normal tissues were derived from neigh-
boring site outside of the tumor. The tissue was immediately
placed in cryovials, frozen in liquid nitrogen, and stored at
80°C until analysis. Both tumor and adjacent nontumor
tissues for subsequent quantitative real-time polymerase
chain reaction (Q-RT-PCR) studies were confirmed by pa-
thologists. RNA preparation and analysis were performed
according to the previous study.28 Briefly, the quality of the
total RNA was determined using Spectra Max Plus (Molec-
ular Devices/MDS Analytical Technologies, Toronto, Can-
ada) and had an OD260/OD280 ratio ranging from 1.9 to 2.1.
RNA was subjected to reverse transcription with random
hexamer primers. To hydrolyze contaminating DNA in the
RNA preparations, RNA was incubated with amplification-
grade DNase I (Life Technologies, Carlsbad, CA). After
incubating the reaction mixture, the reaction was stopped by
heating at 65°C. After DNase treatment, the RNA was sub-
jected to reverse transcription reaction by the ThermoScript
RT-PCR system (Life Technologies), and complementary
DNAs (cDNAs) were then used in the Q-RT-PCR.
Quantitative Real-Time Polymerase Chain
Reaction
Q-RT-PCR was used to measure the mRNA expression
levels between adjacent normal and lung tumors by using
384-well plates (ABI PRISM 7900HT Sequence Detection
System, Applied Biosystems/Life Technologies, Carlsbad,
CA). The cDNAs were served as templates (diluted 200)
for Q-RT-PCR by using TaqMan Universal PCR Master Mix
kit (Applied Biosystems/Life Technologies). Each 10 ml of
Q-PCR reaction mixture contained 5 ml of 2 TaqMan
Universal Master Mixture (Applied Biosystems/Life Tech-
nologies), 4 ml of 200 diluted cDNA product mixture, and
1 ml of PCR forward and reverse primers and probe. To
standardize the quantification of the selected target genes,
DDX5 served as internal controls27 and was quantified on the
same plate as the target genes. The cycle threshold (CT) value
of DDX5 was used to normalize the target gene expression
values, referred to as the CT, which was used to adjust
differences among samples. The reaction products analyzed
by agarose gel electrophoresis showed that many of the
amplifications contained no detectable PCR product. The
Assays-on-Demand IDs (Applied Biosystems/Life Technol-
ogies) for SLAN and DDX5 are Hs00299746 m1 and
Hs00189323 m1. On the basis of paired adjacent normal
and tumor samples of 24 patients, we used Wilcoxon signed-
rank test to determine statistic significance.
Cell Culture
The cell lines used in this study were purchased from
American Type Culture Collection. The culture condition for
293T and HeLa is Dulbecco/Vogt Modified Eagle’s Minimal
Essential Medium with 5% fetal bovine serum, A549, H1299,
and H460 in Roswell Park Memorial Institute 1640 with 10%
fetal bovine serum, 1% nonessential amino acids, and 1%
sodium pyruvate. Moreover, 2 mM glutamine, 100 U/ml
penicillin, and 100 g/ml streptomycin were added in all
media. All cell culture-related reagents were purchased from
Invitrogen-Gibco-Life technologies (Carlsbad, CA). Cells are
maintained in a humidified incubator at 37°C in the presence
of 5% CO2.
Preparation of Cell Extracts, Western Blot
Analysis, and Immunocoprecipitation
The cell extracts were prepared by extraction buffer,
which consists of 50 mM Tris pH 7.5, 0.1% sodium dodecyl
sulfate (SDS), 1% NP40, 0.5% sodium deoxycholate, 1%
Triton X-100, 5mM ethylenediaminetetraacetic acid, 150 mM
NaCl, and 150 mM KCl. Protein concentrations were deter-
mined using the Bradford assay (Bio-Rad Laboratories, Her-
cules, CA). Equal amounts of total lysates were used for
further analyses or loaded onto a 10% SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) and then transferred onto a
polyvinylidene fluoride (PVDF) membrane. The PVDF mem-
brane was blocked with 5% skim milk/Tris buffered saline
with Tween 20 (TBST) (150 mM sodium chloride, 20 mM
Tris, 0.1% Tween-20, pH 7.6). Primary antibodies were
incubated with the membrane as the titer of 1:1000 at 4°C for
2 hours. The membranes were washed with TBST at room
temperature for 10 minutes and repeated for three times.
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Secondary antibodies conjugated with alkaline phosphatase
were added for 1 hour at room temperature followed by
washing with TBST 30 minutes for three times. 5-Bromo-4-
chloro-3-indolyl phosphate and p-Nitro-Blue tetrazolium
chloride (Zymed Laboratories, San Francisco, CA) were
added to develop the membrane.
Indirect Immunofluorescence Analysis
Cells were washed with phosphate-buffered saline
(PBS) and fixed with cold methanol at20°C for 20 minutes.
Sequentially, cells were incubated with primary antibodies at
room temperature for 1 hour followed by wash three times
with TBST and then incubated with secondary antibody—
Tetramethyl Rhodamine Iso-Thiocyanate or fluorescein iso-
thiocyanate (Santa Cruz Biotechnology, Delaware Avenue,
CA) and 4,6-diamidino-2-phenylindole (DAPI; Sigma, MO)
for 1 hour. After washing with TBST, the samples were
mounted with 90% glycerol containing antifading reagent
p-phenylenediamine. The fluorescence images on the cover-
slips were analyzed using an Olympus fluorescence micro-
scope (Olympus Model BX51, Japan).
Flowcytometric Analysis and Mitotic Index
Briefly, 1  106 cells were trypsinized, washed with
PBS, and fixed in 70% ethanol, then washed with PBS,
incubated with 100 g/ml RNase at 37°C for 30 minutes,
stained with propidium iodide (50 g/ml), and analyzed on a
FACScan flow cytometer. The percentage of cells in different
phases of the cell cycle was analyzed using Cell-FIT software
(Becton-Dickinson, Mountain View, CA). The mitotic index
was measured by visualization of cells with propidium iodide
staining under fluorescent microscopy. Approximately, 200
cells were counted at each time point. Cells in mitosis were
judged by the appearance of condensed chromosomes.
Construction of SLAN Expression Vectors
pEGFP-SLAN was obtained by PCR cloning adopting
human full-length SLAN cDNA clone purchased from mamma-
lian genome collection American Type Culture Collection (no.
MGC-26224) as a template. Two primers with RsrII cutting site,
so called CPO site, forward (5-GATGACGGTCCGGAC-
CGAGCCCCCACGGAGC-3) and reverse (5-GTACACG-
GACCGTTACGTAGTTTGCGTTGTGTAATTAG-3), were
used to amply SLAN cDNA by thermocycler machines (Gene-
Amp PCR System 9600, Perkin-Elmer, Waltham, MA). The
first amino acid of SLAN was removed by skipping the first
code in the sequence of PCR primer, which ensures the forma-
tion of enhanced yellow-green variant of green fluorescent
protein (EGFP)-SLAN fusion protein after transfection of cul-
tured cells. The PCR product was then applied to RsrII digestion
(New England Biolabs, MA) to create CPO cloning sites. On the
other hand, pEGFP-C1 vector (Invitrogen-Gibco-Life technolo-
gies) with CPO site created previously was also treated with
RsrII followed by a dephosphorylation reaction to prevent self-
ligation. The resulted linearized vector was then ligated to the
SLAN cDNA with T4 DNA ligation enzyme (New England
Biolabs, MA). Each deletion construct was created by using
corresponding restriction enzyme set, such as RsrII and HindIII
for 2-455, and CPO and HindIII for 2-599 and then ligated to
linearized EGFP empty vector. pEYFP-endoplasmic reticulum
(ER) (BD Biosciences Clontech, Mountain View, CA) encodes
a fusion protein consisting of enhanced yellow fluorescent pro-
tein (EYFP), the ER targeting sequence of calreticulin, which is
cloned at the 5 end, and the sequence encoding the ER retrieval
sequence, KDEL, which is cloned at the 3 end.
Knockdown of SLAN
The SLAN shRNAs used in the studies were purchased
from Academia Sinica (Taipei, Taiwan). The sequences of the
short hairpin RNAs are listed below with underlined SLAN target
sequences: C, CCGGCCTGATTACTTGTTACCCATTCT-
CGAGAATGGGTAACAAGTAATCAGGTTTTTG; D,
CCGGCGATCTCTGAAGTAAATGAAACTCGAGTTTC-
ATTTACTTCAGAGATCGTTTTTG; E, CCGGCGCCT-
GTTTCTACAGAGTATACTCGAGTATACTCTGTAGA-
AACAGGCGTTTTTG; F, CCGGCCATGAATCATGT-
GGAATCATCTCGAGATGATTCCACATGATTCATGG-
TTTTTG; G, CCGGGCCTCATTTGTGGAAAGTGAT-
CTCGAGATCACTTTCCACAAATGAGGCTTTTTG. The
cells were transfected with the shRNAs first. After 24 to 72
hours, cells were harvested for protein expression or applied
to related analyses such as cell proliferation assay or flow
cytometry.
Cell Proliferation Assay
Cells were seeded in 24-well plates and transfected
with desired constructs tagged with EGFP. After a day, the
cells were replated with low density to 10-cm dish, so that
cells could not contact each other. The cells were allowed to
proliferate for 36 hours, and the percentage of cells with
proliferation judged by formation of “mini-colony” with cell
number 2 was counted. If cells could not proliferate, they
remained single in the 10-cm dish after 36-hour culture.
RESULTS
SLAN is Down-Regulated in Collected Lung
Cancer Tissues
To analyze the expression pattern of SLAN in cancer
tissues, we have performed Q-RT-PCR in 24 pairs of lung
cancerous and adjacent normal tissues. SLAN was found
down-regulated in a great portion of the cancer biopsies
(Figure 1A). The comparison between the expression of
SLAN in pooled cancerous and pooled normal tissues re-
vealed a significant p value (Figure 1B).
Motif Prediction and Subcellular Localization
of SLAN
SLAN is a protein with 1101 amino acids. The protein
sequence of SLAN is highly conserved in vertebrate (Supple-
mentary Figure 1A, SDC 1, http://links.lww.com/JTO/A70),
revealing the potential importance of SLAN. There is no homo-
logue found in insects and lower eukaryotes. There are some
putative functional motifs/domains in human SLAN obtained
from sequence prediction such as ER membrane retention signal
(2DRAP5), nuclear localization signals (NLS; 246RRRR249,
396PKRAKSQ402, and 425KKLQEALSKAAGKKNK441), PEST
motifs (252HPTAESSSEQDIDSDSGYCSPKHSNNPQAA286 and
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924RDLLNSSITSTTSTLVPGMLEEEEDEDEEEEEDYTH959), a
sumoylation site (360KDE362), a D box (490RKPL493), a ribo-
somal L7Ae Gadd45 signature (676GLREVTKHMKLNK-
IKCVIISPNCEK700), a tyrosine kinase phosphorylation site
(704kggldealy712), and a coiled coil domain (754GAESLF-
NKLVELTEEARKAYKDMVAAMEQEQAEEALK790). Col-
lectively, the motif prediction suggests SLANmight be localized
to many subcellular compartments and could be subjected to a
number of posttranslational modifications. To uncover the
subcellular localization of SLAN, indirect immunofluores-
cence using anti-SLAN antibody was performed in A549
cells. SLAN was detected distributed around the microtubule
network in interphase (Supplementary Figure 1A, SDC 1,
http://links.lww.com/JTO/A70), which provides a framework
for the ER formation. Moreover, DsRed-SLAN was colocal-
ized to where EYFP-ER marker resided (Supplementary
Figure 1C, SDC 1, http://links.lww.com/JTO/A70), in line
with the prediction that SLAN has an ER membrane retention
signal. When cells progressed to mitosis, SLAN was found
associated with spindle pole with amorphous but not
fiber-like appearance (Supplementary Figure 1B, SDC 1,
http://links.lww.com/JTO/A70). Sequentially, SLAN moved to
spindle midzone and midbody in telophase and cytokinesis.
To dissect the cis elements of SLAN controlling the
subcellular localization of the protein, a series of SLAN deletion
mutants were created and expressed in 293T cells. As shown in
Figure 2C, SLAN full length and its truncate mutants resided at
nucleus, nucleolus, nuclear matrix but not nucleolus, spindle
pole, and whole cell. Careful calculation (Supplementary
Figure 1D, SDC 1, http://links.lww.com/JTO/A70) reveals
that SLAN contains two NLS, two nucleus export signals,
and a nucleolus localization signal (Supplementary Figure
1E, SDC 1, http://links.lww.com/JTO/A70).
SLAN is Associated with Spindle Matrix-Like
Structure
Similar to the pattern of endogenous SLAN in A549
mitotic cells, EGFP-SLAN was localized to the proximity of
spindle pole in the mitosis of H1299, 293T, and HeLa (Figure
2A), resembling so called spindle matrix in appearance.29
Spindle matrix is reported sensitive to detergent but not
nocodazole in frog and fly,29,30 prompting us to examine the
distribution of SLAN in mitosis treated with the two reagents,
respectively (Figure 2B). Incubation of cells with nocodazole
depolymerized spindle and disrupted SLAN; on the other
hand, Triton X-100 did not interfere with spindle but dis-
turbed the association of SLAN with spindle matrix-like
structure, implying a novel property of the SLAN-associated
structure.
SLAN Retards Cell Proliferation by Disturbing
Mitosis
The negative association of SLAN with lung cancer
tissues fueled us to test the effect of SLAN overexpression or
knockdown on cell proliferation. Because the stable cell line
overexpressing exogenous SLAN could not be established, the
cell proliferation assay based on transient expression of
EGFP-SLAN was performed. Most of the cells overexpress-
FIGURE 1. Underexpression of SLAN in lung cancer tissues. A, The mRNA expression level of SLAN was determined by Q-RT-
PCR in 24 pairs of lung cancer and adjacent normal tissues. The experiments were performed in triplicate, and the results
were normalized against the expression level of DDX5 mRNA in each sample and plotted with white bar as tumor and black
bar as normal tissue. B, The box plot shows the data distribution as a grouping classification and indicates that there is a sta-
tistically significant difference between the pooled tumor tissues and the pooled adjacent nontumor tissues by Wilcoxon
signed-rank test. SLAN, suppressed in lung cancer; Q-RT-PCR, quantitative real-time polymerase chain reaction; mRNA, mes-
senger RNA.
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ing EGFP-SLAN failed to proliferate in both cell lines (Fig-
ures 3A, B). By contrast, SLAN shRNAs knocked down
SLAN and accelerated cell proliferation (Figure 3C). More-
over, knockdown of SLAN in 293T cells stimulated cell
proliferation in medium containing 0.1% serum, where con-
trol cells almost ceased growing (Figure 3D), indicating that
depletion of SLAN offers cells advantage to grow in the
environment without sufficient serum.
To dissect the mechanisms by which SLAN or SLAN
shRNA inhibits or stimulates cell proliferation, we examined
the effect of exogenous SLAN or SLAN shRNA on cell cycle
progression (Figure 4A). The 293T cells harboring EGFP,
EGFP-SALN, or SLAN shRNA were subjected to flowcyto-
metric analysis. EGFP-SLAN arrested cells in G2/M, and
hence, cell cycle could not progress to G1, leading to a
reduction of G1; on the contrary, knockdown of SLAN accel-
erated G2/M and S, resulting the accumulation of G1. To
closely and continuously examine the effect of SLAN on cell
proliferation, the cells overexpressing EGFP or EGFP-SLAN
were applied to time-lapse microscope. As expected, the cells
overexpressing EGFP had normal mitosis progression (Figure
4B, upper), which went through mitosis within 80 minutes.
Intriguingly, the cells harboring EGFP-SLAN either arrested
in mitosis (Figure 4B, middle) or left mitosis with a failed
cytokinesis, which in turn produced binucleated cells (Figure
4B, lower). Approximately, 40% or 9% of EGFP-SLAN
expressing cells were binucleated or arrested in mitosis (Fig-
ures 4C, D), roughly matching the difference in the cell
proliferating activity between EGFP or EGFP-SLAN trans-
fected 293T cells (Figure 3B). In addition to SLAN full
length, various SLAN deletion mutants were shown to stop
mitosis with different potency. SLAN 2–551 induced the
highest mitotic arrest (Figure 4E), disturbed the localization
of - and -tubulin, and triggered subsequent malformation
of spindle (Figure 4F).
SLAN Binds and Inactivates Aurora-A
To unravel the molecular activity of SLAN, we initi-
ated a screening for its interaction proteins. Luckily, one of
the mitosis regulators Aurora-A interacted with C-terminal of
SLAN (Figures 5A, B), consistent with previous prediction
that there is a coiled-coil domain at SLAN C-terminal, which
functions for protein-protein interaction. Besides, the inter-
action of Aurora-A and SLAN was independent on the kinase
activity of Aurora-A (Figure 5C). Partial colocalization of
SLAN and Aurora-A was detected in 293T cells (Figure 5D).
Interestingly, SLAN could reduce the level of active Auro-
ra-A in cells (Figure 5E) and inhibited the autophosphoryla-
tion of Aurora-A and Aurora-A-catalyzed phosphate incor-
poration into an artificial substrate myelin basic protein in in
vitro kinase reactions (Figure 5F). Collectively, the SLAN
down-regulated in lung cancer tissues with an inhibitory
activity on cell proliferation is shown to inactivate an onco-
genic kinase Aurora-A.
Underexpression of SLAN and Overexpression
of Aurora-A are Detected in Lung Cancer
Tissues
Aurora-A is a well-documented oncoprotein associated
with a wide range of human malignancies including lung
cancer.5–7 On the other hand, SLAN possesses anticell pro-
liferating activity and is able to inhibit Aurora-A, indicating
SLAN is epistatic to Aurora-A. Accordingly, it is logically
assumed that cancer tissues with up-regulated Aurora-A have
to develop in the genetic background with down-regulated
SLAN. To confirm the idea, 10 pairs of lung tissues containing
tumor (T) or adjacent normal (N) tissues were subjected to
Western blot adopting anti-SLAN, anti-Aurora-A, or anti-
actin antibody (Figure 6A) followed by determination of the
band intensity by densitometer (Figures 6B, C). Among the
FIGURE 2. SLAN is associated with spindle matrix-like structure. A, EGFP-SLAN is localized to the vicinity of spindle without
fiber appearance in H1299, 293T, and HeLa. The three different cells transfected with EGFP-SLAN were subjected to immuno-
fluorescence using anti--tubulin antibody. DNA was labeled with DAPI. B, The distribution of SLAN is sensitive to nocodazole
or Triton X-100. H1299 cells harboring EGFP-SLAN were challenged with 1 g/ml nocodazole for 8 minutes or 0.01% Triton
X-100 for 10 minutes and then applied to immunofluorescence adopting anti--tubulin antibody. DNA was labeled with
DAPI. SLAN, suppressed in lung cancer; EGFP, enhanced yellow-green variant of green fluorescent protein; DAPI, 4,6-di-
amidino-2-phenylindole.
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10 collected lung cancer tissues, Aurora-A was up-regulated
in nine biopsies, among which seven tumor tissues had low
level of SLAN, indicating most of the collected biopsies with
elevated expression of Aurora-A grew into tumors when
SLAN was reduced.
DISCUSSION
According to our analyses, several lines of evidence
suggest a potential inhibitory effect of SLAN on tumor
growth. First, SLAN mRNA and protein are reduced in lung
cancer tissues. Loss of the DNA region covering SLAN gene
locus is reported in several different human cancers (Supple-
mentary Table, SDC 2, http://links.lww.com/JTO/A71). Sec-
ond, overexpression of exogenous SLAN inhibits cell prolif-
eration. By contrast, knockdown of SLAN stimulates cell
proliferation, even in low-serum environment. At last, SLAN
reduces the level of active Aurora-A in cells and directly
inhibits the kinase activity of the latter, an oncoprotein
overexpressed in more than 20 human cancers.
SLAN is a protein with multiple subcellular localizations.
SLAN contains an ER membrane retention signal and is colo-
calized with EYFP-ER marker. SLAN has two NLS and two
nucleus export signals, indicating a complicated regulation of
SLAN shuttling between nucleus and cytoplasm. SLAN
2-599 is associated with nucleolus, and the number of nucle-
olus is increased when SLAN 2-599 is overexpressed (Sup-
plementary Figure 2, SDC 3, http://links.lww.com/JTO/A72).
Together with the observation that SLAN contains a ribo-
somal L7Ae/Gadd45 signature, which is usually found in
ribosomal proteins or proteins engaged in transfer RNA
FIGURE 3. SLAN hampers cell proliferation. A and B, SLAN inhibits cell proliferation; 293T or H1299 cells transfected with
EGFP or EGFP-SLAN for 36 hours were examined with fluorescent microscope, photographed (A), or applied to cell prolifera-
tion assay (B). C, Knockdown of SLAN accelerates cell proliferation; 293T cells transfected with EGFP or EGFP plus each one of
the four different SLAN shRNAs (namely C, E, F, and G) with the molar ratio 1:10 were subjected to Western blot with anti-
SLAN antibody. The excess amount of shRNA may guarantee the expression of SLAN shRNA in EGFP transfected cells. The cell
proliferation assay was parallely performed. D, Knockdown of SLAN stimulates cell growth in low serum; 293T cells transfected
with EGFP or EGFP plus SLAN shRNA-E with the molar ratio 1:10 were subjected to cell proliferation assay. * and *** indicate
statistic significance with p value less than 0.05 and 0.001, respectively, by Student’s t test. SLAN, suppressed in lung cancer;
EGFP, enhanced yellow-green variant of green fluorescent protein; shRNA, short hairpin RNA.
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processing, ribosomal RNA modification, ribosome biogen-
esis, and translation termination,31 all suggest SLAN might
have a role in ribosome biogenesis or translation. In addition,
SLAN is localized to the vicinity of spindle pole with fuzzy
appearance, which is akin to spindle matrix.29 Spindle matrix
is sensitive to detergent but not nocodazole in Drosophila and
Xenopus system.29,30 Nevertheless, the distribution of SLAN
is disrupted on the exposure of mammalian cells to both
nocodazole and detergent, different from the reports about
the aspects of spindle matrix in frog and fly. The obser-
vation argues that either SLAN is attached to an unknown
structure associated with spindle or the mammalian spindle
matrix has distinct property. Moreover, SLAN blocks
cytokinesis and is found located at midbody at the last step
of mitosis, where a contractile ring is formed to execute
the separation of cytoplasm, thereby hinting that SLAN
might monitor and prevent the premature execution of
cytokinesis. On the other hand, SLAN 2-551 or 2-599
mutant is detected on spindle pole. Overexpression of the
two mutants triggers the malformation of spindle pole,
suggesting SLAN has the potential to bind spindle, which
might be important to the maintenance of spindle morphol-
FIGURE 4. SLAN regulates mitosis. A, Overexpression of SLAN per se or its shRNA affects the proportion of G2/M; 293T cells
transfected with EGFP, EGFP-SLAN, or SLAN shRNA-E were applied to flow cytometer. The percentage of cells residing in each
phase of a cell cycle was calculated and plotted. B, Time-lapse recording of cells harboring EGFP-SLAN; 293T cells transfected
with EGFP or EGFP-SLAN were applied to time-lapse microscopic analyses. One and two representatives of EGFP and EGFP-
SLAN transfected cells were displayed with time sequence labeled on the top. The arrows indicate two nuclei due to failure of
cytokinesis in the cell. C and D, SLAN increases the percentage of binucleated cells and mitotic cells; 293T cells transfected
with EGFP or EGFP-SLAN were fixed and stained with DAPI, and the percentage of binucleated cells (C) or mitotic cells (D)
were counted. E, SLAN full length and deletion mutants partially arrest cells in mitosis; 293T cells transfected with EGFP or
various deletion constructs of EGFP-SLAN were stained with DAPI and examined with florescence microscope. The percentage
of cells residing in mitosis was counted and plotted. F, SLAN 2-551 disturbs - and -tubulin; 293T cells transfected with
EGFP-SLAN 2-551 were applied to immunofluorescence with anti--tubulin or anti--tubulin antibody. *, **, and *** represent
statistic significance by Student’s t test with p less than 0.05, 0.01, and 0.001, respectively. SLAN, suppressed in lung cancer; EGFP,
enhanced yellow-green variant of green fluorescent protein; DAPI, 4,6-diamidino-2-phenylindole; shRNA, short hairpin RNA.
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ogy. Taken together, all the collected data reveal that
SLAN is a protein potentially with multiple signals guid-
ing the protein to several subcellular locations and endow-
ing the protein with activities to deal with many aspects of
cell physiology.
Overexpression of SLAN inhibits cell proliferation,
leading to the failure of establishing SLAN stable clones in
several cell lines. Flowcytometric analysis reveals that exog-
enous SLAN increases G2/M portion, and time-lapse record-
ing shows that the SLAN either arrests cells in mitosis or
blocks cytokinesis, which keeps cell number as one after
long-term incubation. Moreover, it is worth pointing out that
the summation of the percentage of the cells arrested in
mitosis and the cells with blocked cytokinesis is almost
equivalent to the difference of proliferating cells between
cells overexpressing EGFP-SLAN and EGFP empty vector,
indicating the inhibitory effect of SLAN on cell proliferation
can be perfectly explained by the arrest of cells in mitosis and
the blockage of cytokinesis. It remains completely obstacle
about how SLAN regulates mitosis progression and cytoki-
nesis. Nevertheless, the findings that SLAN is localized to the
proximity of spindle pole and midbody, and SLAN 2-551 or
FIGURE 5. SLAN binds and inactivates Aurora-A. A, Interaction of SLAN with Aurora-A; 293T cells transfected with EGFP-
SLAN were treated with nocodazole to enrich mitotic cells and then applied to immunoprecipitation using antibody against
Aurora-A (left) or GFP (right). Subsequently, Western blot using antibody against GFP or Aurora-A was conducted. The molec-
ular weight of Aurora-A is 46 kD, slightly smaller than Immunoglobulin G heavy chain (IgG-H). B, Aurora-A binds to SLANs
C-terminal; 293T cells transfected with EGFP-SLAN 2-599 or 474-1101 were exposed to nocodazole and then applied to cell
extract preparation and immunoprecipitation with antibody against Aurora-A. Western blot was then followed with antibody
against GFP or Aurora-A. C, The kinase activity of Aurora-A is not required for the interaction with SLAN; 293T cells trans-
fected with EGFP-SLAN 474-1101 and FLAG-Aurora-A WT or kinase dead (KD) mutant were subjected to immunoprecipitation
with antibody against FLAG and which was followed by Western blot using anti-GFP or FLAG antibody. D, Partial colocaliza-
tion of SLAN and Aurora-A; 293T cells cotransfected with EGFP-SLAN and Aurora-A-DsRed were fixed, permeabilized, and
stained with DAPI followed by examination with fluorescence microscope. E, Overexpression of exogenous SLAN reduces the
level of active Aurora-A. EGFP or EGFP-SLAN was expressed in 293T cells followed by cell extract preparation and Western blot
using antibody against SLAN, Aurora-A or phospho-Aurora-A at threonine 288, which represents activated Aurora-A. F, SLAN
inhibits the activity of Aurora-A. EGFP or EGFP-SLAN was overexpressed in 293T cells followed by isolating EGFP or EGFP-SLAN
by performing immunoprecipitation using antibody against GFP. The purified EGFP or EGFP-SLAN was added to an in vitro
kinase reaction buffer containing recombinant Aurora-A, (-P33)-ATP, and an artificial substrate MBP. The resulted samples
were applied to SDS-PAGE, transblotting, and autoradiography or Western blot using anti-GFP antibody. Sup, supernatants;
ppt, pellets; MBP, myelin basic protein, SLAN, suppressed in lung cancer; EGFP, enhanced yellow-green variant of green fluo-
rescent protein; DAPI, 4,6-diamidino-2-phenylindole; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis;
WT, wild type; GFP, green fluorescent protein; ATP, adenosine triphosphate; MBP, myelin basic protein.
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2-599 is associated with spindle pole and able to disturb
tubulin may provide clues to the future exploration of the
corresponding issues.
SLAN binds and inactivates Aurora-A. Aurora-A is an
oncokinase transmitting oncogenic signaling through its func-
tional kinase activity21 and in turn relaying that to its down-
stream substrates.32 Therefore, inactivation of Aurora-A be-
comes a powerful strategy to the anticancer therapy. Indeed,
Aurora-A inhibitors are developed extensively and have sig-
nificant effects on preventing cancer growth in vitro, animal
models, and clinical trials.11,15,33–37 SLAN diminishes the
activity of Aurora-A by the following observations: first,
SLAN lowers the amount of active Aurora-A in cells; second,
SLAN blocks autophosphorylation of Aurora-A in in vitro
kinase reactions, which is an indicator for the judgment of
kinase activity; and third, SLAN abolishes Aurora-A-cata-
lyzed phosphate incorporation into the artificial substrate
myelin basic protein. Moreover, when the scenario comes to
clinical biopsies, the coincidence of simultaneous up-regula-
tion of Aurora-A and down-regulation of SLAN is frequently
detected in collected lung cancer tissues, which principally
allows cancer tissues develop vigorously because Aurora-A
can have better activity in absence of SLAN. It is, therefore,
extremely important to correlate the cancer stages or patient
survival with the expression pattern of Aurora-A and SLAN
in a large number of biopsies. Collectively, Aurora-A is a
well-known oncoprotein, and SLAN acts similar to a poten-
tial tumor suppressor. The inhibitory effect of SLAN on the
activity of Aurora-A could provide a new molecular approach
to deal with Aurora-A-dependent cancer incidences.
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